TME Pharma Provides Results of First Exercise of Warrants Z

Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides results of the first exercise of Warrants Z and an update on the outstanding number of ordinary shares and Warrants Z as of the settlement date taking place today. The exercise of 479,624 Warrants Z has resulted in the issuance of 599,530 new shares for gross proceeds of €119,906.

In the first Warrant Z exercise period, from February 26 to March 22, 2024, holders were entitled for every 4 Warrants Z held to subscribe for 5 new shares at €0.20 per share. Following this exercise, 3,326,104 outstanding Warrants Z remain with the potential to raise an additional €831,526 if exercised in full before the end of the final exercise period on June 20, 2025.

The following numbers of TME Pharma securities are thus issued and outstanding:

• ALTME ordinary shares (ISIN: NL0015000YE1): 28,453,373
• Warrants Z (ISIN: NL0015001SR3): 3,326,104

The second Warrant Z exercise period will run from May 27 to June 21, 2024, with settlement on June 28, 2024. Warrants Z may be exercised through June 20, 2025, with one period of exercise per quarter (six periods of exercise in total; see “Warrant Terms and Conditions” on the TME Rights Issue page for more details). Warrants Z that have not been exercised by the end of the last exercise period will become null and void.

Additional Information

The characteristics, terms and conditions and dilution resulting from the transaction are summarized in the press releases published on November 24, 2023, November 28, 2023, and February 23, 2024, and in the dedicated Rights Issue page on the TME Pharma website.

Dilution

The table below summarizes the dilution from the new ordinary shares issued today, and the maximum additional dilutive potential for an investor who did NOT participate in the transaction should all potential Warrants Z be exercised. Shareholders who participated fully in the transaction will not be diluted by this transaction.

Description

Shares to be issued

Total shares outstanding

Dilution (cumulative)

Shareholder starting with 1% on Mar 27, 2024, would then hold